Valneva SE
F:AYJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Valneva SE
F:AYJ
|
FR |
|
Palantir Technologies Inc
LSE:0A7R
|
US |
|
F
|
Fresenius Medical Care AG & Co KGaA
XBER:FME
|
DE |
|
Five Below Inc
NASDAQ:FIVE
|
US |
|
M
|
McKesson Europe AG
XHAM:CLS1
|
DE |
|
I
|
ITV PLC
OTC:ITVPF
|
UK |
|
N
|
Nordstrom Inc
DUS:NRD
|
US |
|
Alphabet Inc
MIL:1GOOGL
|
US |
|
S
|
SSE PLC
DUS:SCT
|
UK |
|
Z
|
Zions Bancorporation NA
DUS:ZB1
|
US |
|
D
|
Diageo PLC
SWB:GUIA
|
UK |
Valneva SE
Valneva is a vaccine company. It develops, makes, and sells vaccines that help prevent infectious diseases, with a focus on travel and other niche areas where public health agencies and doctors need specific protection rather than broad everyday medicines. Its best-known products include vaccines for diseases such as Japanese encephalitis, cholera, and other travel-related infections, along with vaccine candidates still in development. The company sells mainly to governments, public health buyers, travel clinics, hospitals, and pharmacies, depending on the vaccine. It makes money by selling finished vaccines and, in some cases, by working with partners on development, manufacturing, or licensing agreements. That means its revenue comes from a mix of product sales and collaboration income, rather than from repeat prescriptions or generic drug volume. What makes Valneva different is that it sits in a narrow part of the healthcare market: vaccines are highly regulated, take a long time to develop, and are usually bought for prevention rather than treatment. That gives the business a long product-development cycle and a strong link to public health needs, travel patterns, and government purchasing decisions.
Valneva is a vaccine company. It develops, makes, and sells vaccines that help prevent infectious diseases, with a focus on travel and other niche areas where public health agencies and doctors need specific protection rather than broad everyday medicines. Its best-known products include vaccines for diseases such as Japanese encephalitis, cholera, and other travel-related infections, along with vaccine candidates still in development.
The company sells mainly to governments, public health buyers, travel clinics, hospitals, and pharmacies, depending on the vaccine. It makes money by selling finished vaccines and, in some cases, by working with partners on development, manufacturing, or licensing agreements. That means its revenue comes from a mix of product sales and collaboration income, rather than from repeat prescriptions or generic drug volume.
What makes Valneva different is that it sits in a narrow part of the healthcare market: vaccines are highly regulated, take a long time to develop, and are usually bought for prevention rather than treatment. That gives the business a long product-development cycle and a strong link to public health needs, travel patterns, and government purchasing decisions.
Lyme setback, but still alive: Valneva said the Lyme Phase III readout missed the first prespecified statistical criterion, though the second was met and Pfizer is planning regulatory submissions. Management said the efficacy was still above 70% and there were no safety concerns.
Cost reset: In response to uncertainty around Lyme, Valneva launched a restructuring plan that includes a global workforce reduction of about 10% to 15% and aims to cut operating expenses by 25% to 35% versus last year.
Revenue pressure: First-quarter product sales were EUR 30.5 million, down from EUR 48.6 million a year ago, driven mainly by DoD shipment timing for IXIARO, lower DUKORAL sales after a one-off prior-year shipment, and lower third-party product sales.
Guidance cut: Full-year 2026 product sales guidance was lowered to EUR 135 million to EUR 150 million and total revenue guidance to EUR 145 million to EUR 160 million, reflecting softer travel vaccine uptake and geopolitical uncertainty.
Cash remains solid: Valneva ended March with EUR 105 million in cash and cash equivalents, before the April 2026 proceeds from its reserved offering.
Pipeline still active: Management highlighted ongoing work in chikungunya, Shigella and preclinical EBV, and said it still sees Lyme success as a major strategic upside for the company.
